# Therapy Optimization in Multiple Sclerosis (MS)

> **NCT00819000** · — · COMPLETED · sponsor: **Teva Neuroscience, Inc.** · enrollment: 2878 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

## Key facts

- **NCT ID:** NCT00819000
- **Lead sponsor:** Teva Neuroscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 2878 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819000, "Therapy Optimization in Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00819000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*